We are live on ! Find out more
PLRX icon

Pliant Therapeutics

1.17 USD
+0.04
3.54%
At close Updated Sep 11, 4:00 PM EDT
1 day
3.54%
5 days
4.46%
1 month
13.59%
3 months
2.63%
6 months
-12.03%
Year to date
-6.4%
1 year
-29.09%
5 years
-93.8%
10 years
-94.51%
 

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Employees: 49

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
26 days ago
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Neutral
GlobeNewsWire
1 month ago
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095,  experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
2 months ago
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Appointments bring global oncology drug development experience  and deepen Board's operational and regulatory expertise
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Neutral
Seeking Alpha
3 months ago
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral
GlobeNewsWire
3 months ago
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095  enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Neutral
GlobeNewsWire
4 months ago
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Neutral
GlobeNewsWire
4 months ago
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keith Cummings, M.D., Pliant's Chief Financial Officer, will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time.
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Neutral
GlobeNewsWire
4 months ago
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1.
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Neutral
GlobeNewsWire
4 months ago
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Neutral
GlobeNewsWire
5 months ago
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Price charts implemented using Lightweight Charts™